SHL — Siemens Healthineers AG Balance Sheet
0.000.00%
Last trade - 00:00
- €56.68bn
- €70.75bn
- €21.68bn
- 70
- 25
- 86
- 66
2019 September 30th | 2020 September 30th | R2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 976 | 771 | 1,462 | 1,666 | 1,829 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4,649 | 7,053 | 5,951 | 6,996 | 7,421 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7,779 | 10,268 | 10,782 | 13,379 | 14,136 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,318 | 2,774 | 3,712 | 4,273 | 4,210 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 21,429 | 25,094 | 41,927 | 49,056 | 46,684 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5,605 | 7,289 | 10,113 | 12,024 | 13,440 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 11,660 | 12,596 | 25,890 | 29,220 | 28,603 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 9,769 | 12,498 | 16,037 | 19,836 | 18,081 |
Total Liabilities & Shareholders' Equity | 21,429 | 25,094 | 41,927 | 49,056 | 46,684 |
Total Common Shares Outstanding |